Skip to main content
Premium Trial:

Request an Annual Quote

In FY 02, Applera s White Pocketed $7.9M; Celera s Ordoez Paid $1.6M; ABI s Hunkapiller Took Home $1.3M

A note to readers: This is the first of a new breed of briefs GenomeWeb will cover. Called Proxy Reports, these briefs will review annual proxy statements issued to the US Securities and Exchange Commission by Genome Technology Index companies.


NEW YORK, Sept. 16 - Applera's three top executives were paid $5 million in salaries, bonuses, and near-term stock options last year, recent filings with the federal securities agency show.


However, exercised stock options, dividends, and perks took that figure significantly higher.


For the fiscal year ended June 2002, Applera CEO Tony White earned a total of $2.4 million, including $1 million in salary, a full bonus of $1.15 million, vested performance units worth $125,000, and perks and dividends totaling $192,044, including personal use of company aircraft worth $155, 012.


He also realized $5.5 million in stock-option gains on Celera and Applera stock, bringing his total compensation to $7.9 million.


White also received options to buy 255,000 shares of Applera-Applied Biosystems and 85,000 shares of Celera-Applied Biosystems, a package estimated to be worth between $5.6 million and $14.3 million by 2012.


Last year, White was paid $25.8 million, including a $24 million restricted stock award, and drew total compensation of $61.9 million, thanks to $27.2 million in stock option gains.


New Celera Diagnostics and Celera Genomics President Kathy Ordoñez came in at $1.6 million, including $374,424 in salary, $420,325 in bonuses, and 40,000 shares of restricted Applera-Celera stock now worth $774,800 that vest over the next three years.


Ordoñez was also awarded options on 85,000 shares of Applera-ABI and 128,000 shares of Celera-ABI that vest fully by 2012. Her package is potentially worth between $2.6 million and $6.7 million.


In the fiscal year ending June 2002, senior vice president Michael Hunkapiller pulled down roughly $1 million, including $529,307 in salary and $462,977 in bonuses, $2,125 in dividends, and payments from vested performance units worth $62,500.


Hunkapiller also realized $253,364 in stock-option gains. He was awarded 141,000 options on shares of Applera-ABI and 34,000 shares of Celera-ABI, estimated to be worth $2.4 million and $6 million by 2012.


For further information, see the company proxy report.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.